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Although carbapenemases in Enterobacteriaceae were relatively
rare a decade ago, their emergence and rapid spread is now an
alarming worldwide problem, for both the scientiﬁc and public
health communities [1]. In the present theme issue, we provide
an overview of the different factors that probably explain the
spread and success of the main carbapenemase producers, and
the current knowledge on epidemiology, genetics, diagnostics,
prevention and surveillance, and treatment.
In the ﬁrst review of this issue, the classiﬁcation, phylogenetic
aspects and different genetic platforms associated with carba-
penemases in Gram-negative bacteria are reviewed [2]. Carba-
penemases are mainly found in Amber classes A, B, and D, with
KPC, NDM and OXA-48 being the most frequently encoun-
tered in Enterobacteriaceae, respectively [2]. Interestingly, this
study shows very large diversity and long-lasting phylogenetic
evolution, with notable variation in the mean GC content and
percentages of identity for the different carbapenemase-encod-
ing genes. Moreover, these genes can be found chromosomally
or on mobile genetic elements such as transposons, integrons,
and plasmids, the latter being widely associated with the
worldwide spread in Enterobacteriaceae. These mobile genetic
elements frequently contain other antibiotic resistance genes,
leading to rapid evolution towards multidrug-resistant bacteria.
The magnitude of the problem is probably underestimated, as
new antibiotic resistance genes may emerge at any time, as was
the case for NDM-1 [3]. In the second review, by Poirel
et al. [4], the current epidemiology of carbapenemases in
Enterobacteriaceae demonstrates that carbapenemase produc-
ers have spread all over the world, and that the situation is
becoming worrying in some countries, especially in the USA,
Greece, Israel and Italy for KPC carbapenemases, in the Indian
subcontinent for NDM carbapenemases, and in North Africa
and Turkey for OXA-48 [4]. NDM and OXA-48 enzymes have
been identiﬁed in both nosocomial and community-acquired
Escherichia coli and Klebsiella pneumoniae, whereas KPC produc-
ers are mainly nosocomial K. pneumoniae isolates. Rapid detec-
tion and identiﬁcation of these genes is critical for the
implementation of health control policies, but detection is
complicated by the low enzymatic activity of some enzymes
(mainly OXA-48). The third review, by Hrabak et al. [5],
summarizes the current screening methods and laboratory
diagnosis methods for carbapenemase detection and identiﬁca-
tion. Carbapenemase producers can be screened by using faecal
or rectal swabs, which are streaked onto commercial cultivation
media for detection of isolates with reduced susceptibility to
carbapenems. Conﬁrmation of carbapenemase activity can be
achieved with phenotypic tests (Modiﬁed Hodge test, inhibition
by chelating agents, combined diskmethods, colorimetric assays,
and matrix-assisted laser desorption ionization time-of-ﬂight
mass spectrometry) or with molecular tests (PCR, real-time
PCR, microarrays, and genome sequencing) [5]. Because there
are only limited therapeutic options for the treatment of
infections caused by carbapenemase producers, infection pre-
vention remains oneof the critical approaches for preventing the
spread of such organisms, and strategies for this are reviewed by
Savard et al. [6]. Prevention practices are critical, because
infections caused by carbapenemase producers are associated
with high rates of morbidity and mortality, prolonged hospital
stays, and overall increased healthcare costs [6]. Thus, it seems
reasonable to conduct epidemiological surveys to identify
carriers who act as reservoir for transmission to others, in
order to implement contact isolation and cohorting for
prevention of transmission. Moreover, epidemiological studies
for surveillance of themagnitude of the problem at local, national
and international levels are also warranted to prevent pandemic
diffusion of new multidrug-resistant clones [6]. Finally, the
review from Tzouvelekis et al. [7] provides a meta-analysis
based on 20 clinical studies on the treatment of infections caused
by carbapenemase-producing Enterobacteriaceae. Treatment of
infections caused by carbapenemase producers is challenging,
because only a few antibiotics (including colistin, tigecycline, and
aminoglycosides) may remain effective, and resistance to these
compounds has also recently emerged in Enterobacteriaceae.
Treatment with a single effective antibiotic is associated with an
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unacceptably high mortality rate, and combination regimens
should be the rule to obtain a clear survival beneﬁt [7].
In conclusion, carbapenemases now represent an unrelent-
ing threat to human health worldwide, and will constitute one
of the most challenging problems confronting containment of
infectious diseases in the years to come.
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